London: A new lung cancer vaccine is being tested on patients for the first time in the UK.
On Tuesday, the UK’s first patient was given the vaccine at the National Institute for Health Research’s UCLH Clinical Research Facility.
Researchers leading the trial say the treatment could improve survival rates in people with the disease and hope it will eventually become the standard of care worldwide.
BioNTech’s vaccine, known as BNT116, is designed to treat non-small cell (the most common type of the disease) lung cancer (NSCLC). .
The vaccine uses messenger RNA (mRNA) and works by providing tumor markers derived from NSCLC to the immune system to expose these markers to prepare the body to fight cancer cells. can be done
